Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Referral delays for arthritis patients could have devastating consequences

I would like to highlight the devastating consequences that delayed referrals are having on people with inflammatory arthritis.

The latest national clinical audit, published by the British Rheumatology Society on 25 July 2016, revealed that a high proportion of NHS services are failing to meet quality standards set by the National Institute for Health and Care Excellence. This includes referral from a GP to a specialist service within three days and assessment in a rheumatology service within three weeks.

Rheumatoid arthritis (and other forms of inflammatory arthritis) are conditions in which the immune system attacks the joints, making them inflamed — hot, red, painful and swollen. These conditions can lead to long-term joint damage, causing chronic pain and disability. Urgent, intensive treatment is needed when these conditions occur to stop inflammation and prevent long-term damage.

The audit found that only 20% of people who see a GP with suspected early inflammatory arthritis are referred within three days, and only 37% of those are seen by a specialist within three weeks.

The audit findings about treatment were more positive; 68% of those diagnosed with rheumatoid arthritis received disease modifying antirheumatoid drugs within six weeks of their diagnosis, an increase of 15% from the previous audit.

Nonetheless, the results of this audit are disappointing and show that people with inflammatory arthritis are not getting the treatment they need fast enough. The impact of delayed treatment can be detrimental and life-changing. Four out of five people with inflammatory arthritis are at risk of long-term disability or reduced life expectancy because of delays.

We urge that immediate action is taken to improve access to services, so that people with inflammatory arthritis get the treatment they need and the quality of life they deserve.

Tracey Loftis

Head of policy and public affairs

Arthritis Research UK

Citation: Clinical Pharmacist DOI: 10.1211/CP.2016.20201522

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.